ArticleTranslational oncology2026
Establishment of a clear cell renal cell carcinoma organoid cohort integrated into the UroCCR clinical database: A feasibility study.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the sixth most common cancer in France. While early-stage survival rates are high in early stages, they decrease significantly in metastatic stages, due to tumor heterogeneity and treatment resistance. The development of reliable preclinical models is essential to improve targeted therapies. This study aimed to evaluate the feasibility of establishing patient-derived ccRCC organoids linked to the UroCCR clinical database. METHODOLOGY: Tumor samples from total or partial nephrectomies performed at Caen University Hospital between November 2023 and March 2024 were processed for organoid culture. Seven culture conditions were tested, including different extracellular matrices (Matrigel, collagen I) and growth factor-enriched media.
resultsOrganoids were established in 12 of 18 cases (66.7%). Among these, five cultures were successfully expanded and characterized histologically (42%). Organoids were maintained in culture for a median of 52 days and underwent a mean of two passages. Histological analyses showed that organoids retained several morphological features consistent with the original tumors, although variability in CA-IX and CK7 expression was observed. SIGNIFICANCE: This feasibility study demonstrates that ccRCC organoid generation from surgical specimens is achievable but remains limited by variable establishment rates and culture duration. Further optimization and integration of microenvironmental components will be necessary to enhance the translational relevance of this model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.